Ionis Pharmaceuticals’ zilganersen, brand name Zanvastro, is the first disease-modifying therapy approved for the neurological disorder Alexander disease. While Ionis has experience developing medicines for rare neuroscience indications, Zanvastro will be the first neurology product the company brings to the market without a commercialization partner.
The post FDA Approves Ionis Pharma Drug, the First for Ultra-Rare Alexander Disease appeared first on MedCity News.
